May 22, 2019 Expands pipeline with ARGX-117 and ARGX-118; two new pipeline candidates from its Innovative Access Program addressing first-in-class targets Highlights formation of two global therapeutic franchises in neuromuscular and hematology with targeted first commercial launch in 2021 Appoints Wim Parys, M.D. as Chief Medical Officer, formerly of Janssen May 22, 2019 Breda, the Netherlands / Ghent, Belgium - argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, will be hosting its second R&D Day today, Wednesday, May 22, 2019, in New York...
|
